Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02565628 · ClinicalTrials.gov registry record · Phase 1
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02565628 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 20 participants.
The verdict
NCT02565628, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is designed to assess safety, tolerability and pharmacokinetic data for multiple doses of PF-06669571 in subjects with idiopathic Parkinson's disease. In addition, this study will assess whether PF-06669571 is able to demonstrate superior efficacy compared with placebo in the treatment of the motor symptoms of idiopathic Parkinson's disease.
Interventions
- DRUG Placebo
- DRUG PF-06669571
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-11-16 |
| Est. Completion | 2016-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02565628
The ClinicalTrials.gov registry entry for NCT02565628 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02565628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02565628 about?
NCT02565628 is a clinical study titled "PF-06669571 In Subjects With Idiopathic Parkinson's Disease". This study is designed to assess safety, tolerability and pharmacokinetic data for multiple doses of PF-06669571 in subjects with idiopathic Parkinson's disease. In addition, this study will assess whether PF-06669571 is able to demonstrate superior efficacy compared with placebo in the treatment of...
What is the current status of trial NCT02565628?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-11-16. Estimated completion is 2016-05-13.
What interventions are being tested in trial NCT02565628?
The interventions under investigation include: Placebo (DRUG), PF-06669571 (DRUG).
Who is sponsoring clinical trial NCT02565628?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.